![[Nle8] Somatostatin (1-28) (TFA)](/upload/1124/V86781.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
[Nle⁸] Somatostatin (1‑28) targets somatostatin receptors (SSTR). Somatostatin is a cyclic tetradecapeptide that acts as an endogenous inhibitor of the release of growth hormone (GH), insulin, glucagon, and other hormones. [Nle⁸] Somatostatin (1‑28) is a synthetic analogue of somatostatin-28, the longer form of somatostatin. The norleucine substitution at position 8 prevents methionine oxidation, which can occur during peptide synthesis or storage, thereby improving the stability and reliability of the peptide. It is used as a reference standard to quantify native somatostatin levels.
|
|---|---|
| ln Vitro |
[Nle⁸] Somatostatin (1‑28) is a synthetic analogue of somatostatin‑28. It is used as a reference standard for the quantification of native somatostatin‑28 in biological samples (e.g., plasma, tissue extracts) by radioimmunoassay (RIA) or LC‑MS. As a stable analogue, it retains full biological activity at somatostatin receptors and is also used as a receptor probe to study somatostatin receptor binding and function. No specific EC₅0 values are reported in the search results.
|
| ln Vivo |
No specific in vivo activity data for [Nle⁸] Somatostatin (1‑28) are reported in the search results. As a stable somatostatin analogue, it is expected to have similar biological activity to native somatostatin‑28, including inhibition of growth hormone (GH) secretion. However, it is primarily used as an analytical standard or a research tool, not as a therapeutic agent. The compound can be used to spike into biological samples as a control for somatostatin measurements.
|
| Enzyme Assay |
[Nle⁸] Somatostatin (1‑28) is used as a reference standard in radioimmunoassays (RIA) for the quantification of somatostatin‑28. The peptide is typically labeled with a radioactive isotope (e.g., ¹2⁵I) for use as a tracer. Unlabeled [Nle⁸] Somatostatin (1‑28) is used to construct standard curves by adding known concentrations (1‑1000 pg/mL) to assay buffer or stripped biological matrix. The binding of the tracer to a somatostatin antibody is competed with by unlabeled peptide, and the concentration is determined by interpolation from the standard curve.
|
| Cell Assay |
No cellular experiments for [Nle⁸] Somatostatin (1‑28) are described in the search results. For analytical studies, the peptide is not used in cellular assays. For receptor binding studies, cells expressing somatostatin receptors (e.g., CHO‑SSTR2 cells) are seeded in 96‑well plates, and the ability of [Nle⁸] Somatostatin (1‑28) to compete with a radiolabeled somatostatin analog for binding to SSTRs is measured. No specific protocols are described.
|
| Animal Protocol |
No animal experiments for [Nle⁸] Somatostatin (1‑28) are described in the search results. For analytical studies, the peptide is used as a standard in pharmacokinetic studies. Animals (e.g., rats) are administered native somatostatin‑28 or a somatostatin analog, blood samples are collected, and [Nle⁸] Somatostatin (1‑28) is added as an internal standard for LC‑MS/MS quantification. No therapeutic animal studies are described.
|
| ADME/Pharmacokinetics |
[Nle⁸] Somatostatin (1‑28) (C13₈H21₈N40O40S, MW = 3100.48, purity ≥95%) is a lyophilized powder. For storage, the powder should be kept at -20 degC or -80 degC, sealed and protected from light. For in vitro use, stock solutions in water or PBS (1‑10 mg/mL) can be prepared and stored at -80 degC for up to 6 months or at -20 degC for 1 month. The TFA salt form is the industry standard for synthetic peptides. No detailed PK parameters are reported.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for [Nle⁸] Somatostatin (1‑28) are reported. As a research‑grade peptide, it is not intended for human or veterinary use. Standard laboratory safety precautions for handling peptides should be followed. The TFA counterion may be irritating but is present in low amounts.
|
| References | |
| Additional Infomation |
Somatostatin is a cyclic peptide hormone that exists in two major forms: somatostatin‑14 (14 amino acids) and somatostatin‑28 (28 amino acids). Both forms are derived from the same precursor, preprosomatostatin. Somatostatin inhibits the release of growth hormone, insulin, glucagon, and other hormones. [Nle⁸] Somatostatin (1‑28) is a stable analogue of somatostatin‑28 where the oxidation‑sensitive methionine at position 8 is replaced by norleucine. This substitution does not alter biological activity but prevents oxidation, ensuring batch‑to‑batch consistency and stability in storage. This compound is widely used as a reference standard in radioimmunoassays and as a stable receptor probe. It is for research use only and has no clinical applications.
|
| Molecular Formula |
C138H209N41O39S2.XC2HF3O2
|
|---|---|
| Molecular Weight |
3130.52 (free base)
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
